Nbeal2 interacts with Dock7, Sec16a, and Vac14

Blood

Volumn 131, Issue 9, 2018, Pages 1000-1011

  Mayer, Louisa ^a,b   Jasztal, Maria ^a,b   Pardo, Mercedes ^c,l   Aguera de Haro, Salvadora ^a,b   Collins, Janine ^a,b,d,l   Bariana, Tadbir K ^a,e,f   Smethurst, Peter A ^a,b   Grassi, Luigi ^a,b   Petersen, Romina ^a,b   Nurden, Paquita ^g   Favier, Rémi ^h,i   Yu, Lu ^c,l   Meacham, Stuart ^a,b,c   Astle, William J ^j   Choudhary, Jyoti ^c   Yue, Wyatt W ^k   Ouwehand, Willem H ^a,b,c   Guerrero, Jose A ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d BARTS HEALTH NHS TRUST   (United Kingdom)

^e ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g Ctr Geriatrie Ctr Hosp Univ B   (France)

^h ARMAND TROUSSEAU HOSPITAL   (France)

ⁱ INSERM   (France)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k UNIVERSITY OF OXFORD   (United Kingdom)

^l INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CALRETICULIN; DOCK7 PROTEIN; F ACTIN; NBEAL2 PROTEIN; PROTEIN; SEC16A PROTEIN; THROMBIN; TRANSCRIPTOME; TUBULIN; UNCLASSIFIED DRUG; VAC14 PROTEIN; DOCK7 PROTEIN, HUMAN; DOCK7 PROTEIN, MOUSE; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MEMBRANE PROTEIN; NBEAL2 PROTEIN, HUMAN; NBEAL2 PROTEIN, MOUSE; PLASMA PROTEIN; PROTEIN BINDING; SEC16A PROTEIN, HUMAN; SEC16A PROTEIN, MOUSE; SIGNAL PEPTIDE; VAC14 PROTEIN, HUMAN; VAC14 PROTEIN, MOUSE; VESICULAR TRANSPORT PROTEIN;

ACTIN POLYMERIZATION; ADULT; ANIMAL CELL; ARTICLE; CELL FRACTIONATION; CELL SURFACE; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CRYSTAL STRUCTURE; ELECTRON MICROSCOPY; EMBRYO; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MEGAKARYOCYTE; MOUSE; NONHUMAN; PLECKSTRIN HOMOLOGY DOMAIN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE SHAPE; THROMBOCYTOPOIESIS; TRANSMISSION ELECTRON MICROSCOPY; WD REPEAT; ANIMAL; CYTOLOGY; GENETICS; HEK293 CELL LINE; KNOCKOUT MOUSE; METABOLISM; MUTATION; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; BLOOD PROTEINS; GTPASE-ACTIVATING PROTEINS; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HEK293 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEGAKARYOCYTES; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MUTATION; PROTEIN BINDING; VESICULAR TRANSPORT PROTEINS;

EID: 85047730357     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-08-800359     Document Type: Article

References (57)

1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8(11):1227-1234.
2. Golebiewska EM, Poole AW. Platelet secretion: from haemostasis to wound healing and beyond. Blood Rev. 2015;29(3):153-162.
3. Gundelfinger ED, Kessels MM, Qualmann B. Temporal and spatial coordination of exocytosis and endocytosis. Nat Rev Mol Cell Biol. 2003;4(2):127-139.
4. de Saint Basile G, Ménasché G, Fischer A. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol. 2010;10(8):568-579.
5. De Matteis MA, Luini A. Mendelian disorders of membrane trafficking. N Engl J Med. 2011; 365(10):927-938.
6. Patel SR, Hartwig JH, Italiano JE Jr. The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest. 2005;115(12): 3348-3354.
7. Jackson SP. Arterial thrombosis–insidious, unpredictable and deadly. Nat Med. 2011; 17(11):1423-1436.
8. Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E. Platelets and wound healing. Front Biosci. 2008;13:3532-3548.
9. Kisucka J, Butterfield CE, Duda DG, et al. Platelets and platelet adhesion support an-giogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci USA. 2006;103(4): 855-860.
10. Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science. 2010;327(5965):580-583.
11. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11(4):264-274.
12. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123-134.
13. Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev. 2009;23(4):177-189.
14. Bariana TK, Ouwehand WH, Guerrero JA, Gomez K; BRIDGE Bleeding, Thrombotic and Platelet Disorders and ThromboGenomics Consortia. Dawning of the age of genomics for platelet granule disorders: improving insight, diagnosis and management. Br J Haematol. 2017;176(5):705-720.
15. Nagle DL, Karim MA, Woolf EA, et al. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat Genet. 1996;14(3):307-311.
16. Masliah-Planchon J, Darnige L, Bellucci S. Molecular determinants of platelet delta storage pool deficiencies: an update. Br J Haematol. 2013;160(1):5-11.
17. Castermans D, Volders K, Crepel A, et al. SCAMP5, NBEA and AMISYN: three candidate genes for autism involved in secretion of large dense-core vesicles. Hum Mol Genet. 2010;19(7):1368-1378.
18. Nuytens K, Tuand K, Di Michele M, et al. Platelets of mice heterozygous for neuro-beachin, a candidate gene for autism spectrum disorder, display protein changes related to aberrant protein kinase A activity. Mol Autism. 2013;4(1):43.
19. Zufferey A, Schvartz D, Nolli S, Reny JL, Sanchez JC, Fontana P. Characterization of the platelet granule proteome: evidence of the presence of MHC1 in alpha-granules. J Proteomics. 2014;101:130-140.
20. Raccuglia G. Gray platelet syndrome. A variety of qualitative platelet disorder. Am J Med. 1971;51(6):818-828.
21. Albers CA, Cvejic A, Favier R, et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet. 2011;43(8):735-737.
22. Kahr WH, Hinckley J, Li L, et al. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat Genet. 2011; 43(8):738-740.
23. Gunay-Aygun M, Falik-Zaccai TC, Vilboux T, et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet a-granules. Nat Genet. 2011;43(8): 732-734.
24. Sowerby JM, Thomas DC, Clare S, et al. NBEAL2 is required for neutrophil and NK cell function and pathogen defense. J Clin Invest. 2017;127(9):3521-3526.
25. Drube S, Grimlowski R, Deppermann C, et al. The Neurobeachin-like 2 protein regulates mast cell homeostasis. J Immunol. 2017; 199(8):2948-2957.
26. Kahr WH, Lo RW, Li L, et al. Abnormal megakaryocyte development and platelet function in Nbeal2(-/-) mice. Blood. 2013; 122(19):3349-3358.
27. Guerrero JA, Bennett C, van der Weyden L, et al. Gray platelet syndrome: proin-flammatory megakaryocytes and a-granule loss cause myelofibrosis and confer metastasis resistance in mice. Blood. 2014;124(24): 3624-3635.
28. Deppermann C, Cherpokova D, Nurden P, et al. Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice. J Clin Invest. 2013;123(8):3331-3342.
29. Cullinane AR, Schäffer AA, Huizing M. The BEACH is hot: a LYST of emerging roles for BEACH-domain containing proteins in human disease. Traffic. 2013;14(7):749-766.
30. Jogl G, Shen Y, Gebauer D, et al. Crystal structure of the BEACH domain reveals an unusual fold and extensive association with a novel PH domain. EMBO J. 2002;21(18): 4785-4795.
31. Gebauer D, Li J, Jogl G, Shen Y, Myszka DG, Tong L. Crystal structure of the PH-BEACH domains of human LRBA/BGL. Biochemistry. 2004;43(47):14873-14880.
32. Pardo M, Lang B, Yu L, et al. An expanded Oct4 interaction network: implications for stem cell biology, development, and disease. Cell Stem Cell. 2010;6(4):382-395.
33. Vizcaíno JA, Csordas A, del-Toro N, et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 2016;44(D1): D447-D456.
34. Nurden P, Jandrot-Perrus M, Combrié R, et al. Severe deficiency of glycoprotein VI in a patient with gray platelet syndrome. Blood. 2004;104(1):107-114.
35. Lentaigne C, Freson K, Laffan MA, Turro E, Ouwehand WH; BRIDGE-BPD Consortium and the ThromboGenomics Consortium. Inherited platelet disorders: toward DNA-based diagnosis. Blood. 2016;127(23): 2814-2823.
36. Jupe S, Akkerman JW, Soranzo N, Ouwehand WH. Reactome - a curated knowledgebase of biological pathways: megakaryocytes and platelets. J Thromb Haemost. 2012;10(11): 2399-2402.
37. Orchard S, Ammari M, Aranda B, et al. The MIntAct project–IntAct as a common curation platform for 11 molecular interaction databases. Nucleic Acids Res. 2014;42(Database issue):D358-D363.
38. Petersen R, Lambourne JJ, Javierre BM, et al. Platelet function is modified by common sequence variation in megakaryocyte super enhancers. Nat Commun. 2017;8:1-12.
39. Astle WJ, Elding H, Jiang T, et al. The allelic landscape of human blood cell trait variation and links to common complex disease. Cell. 2016;167(5):1415-1429.e19.
40. Javierre BM, Burren OS, Wilder SP, et al. Lineage-specific genome architecture links enhancers and non-coding disease variants to target gene promoters. Cell. 2016;167(5): 1369-1384.e19.
41. Simeoni I, Stephens JC, Hu F, et al. A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood. 2016;127(23):2791-2803.
42. Nürnberg ST, Rendon A, Smethurst PA, et al; HaemGen Consortium. A GWAS sequence variant for platelet volume marks an alternative DNM3 promoter in megakaryocytes near a MEIS1 binding site. Blood. 2012;120(24): 4859-4868.
43. Chen L, Kostadima M, Martens JHA, et al. Transcriptional diversity during lineage commitment of human blood progenitors. Science. 2014;345(6204):1251033.
44. Bottega R, Nicchia E, Alfano C, et al. Gray platelet syndrome: novel mutations of the NBEAL2 gene. Am J Hematol. 2017;92(2): E20-E22.
45. Bottega R, Pecci A, De Candia E, et al. Correlation between platelet phenotype and NBEAL2 genotype in patients with congenital thrombocytopenia and a-granule deficiency. Haematologica. 2013;98(6):868-874.
46. Aslan JE, McCarty OJ. Rho GTPases in platelet function. J Thromb Haemost. 2013;11(1): 35-46.
47. Miyamoto Y, Yamauchi J. Cellular signaling of Dock family proteins in neural function. Cell Signal. 2010;22(2):175-182.
48. Malarkannan S, Awasthi A, Rajasekaran K, et al. IQGAP1: a regulator of intracellular spacetime relativity. J Immunol. 2012;188(5): 2057-2063.
49. Tchernev VT, Mansfield TA, Giot L, et al. The Chediak-Higashi protein interacts with SNARE complex and signal transduction proteins. Mol Med. 2002;8(1):56-64.
50. Sviderskaya EV, Novak EK, Swank RT, Bennett DC. The murine misty mutation: phenotypic effects on melanocytes, platelets and brown fat. Genetics. 1998;148(1):381-390.
51. Bender M, Eckly A, Hartwig JH, et al. ADF/n-cofilin-dependent actin turnover determines platelet formation and sizing. Blood. 2010; 116(10):1767-1775.
52. Pleines I, Dütting S, Cherpokova D, et al. Defective tubulin organization and proplatelet formation in murine megakaryocytes lacking Rac1 and Cdc42. Blood. 2013;122(18): 3178-3187.
53. Kauskot A, Poirault-Chassac S, Adam F, et al. LIM kinase/cofilin dysregulation promotes
54. macrothrombocytopenia in severe von Willebrand disease-type 2B. JCI Insight. 2016;1(16):e88643.
55. Côté JF, Motoyama AB, Bush JA, Vuori K. A novel and evolutionarily conserved PtdIns (3,4,5)P3-binding domain is necessary for DOCK180 signalling. Nat Cell Biol. 2005;7(8): 797-807.
56. Cho HJ, Yu J, Xie C, et al. Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export. EMBO J. 2014;33(20): 2314-2331.
57. Jin N, Chow CY, Liu L, et al. VAC14 nucleates a protein complex essential for the acute interconversion of PI3P and PI(3,5)P(2) in yeast and mouse. EMBO J. 2008;27(24): 3221-3234.